« Pharmacologie des agonistes de PPARα et PPARγ et des activateurs PPARα/γ mixtes en

SUMMARY Pharmacology of PPAR α , PPAR γ and dual PPAR α / γ agonists in clinical development Cardiovascular diseases (CVD) remain the leading causeof mortality in the western societies. Several risk factorspredispose to CVD including diabetes, obesity, insulinresistance, dyslipidemia and hypertension. Variouspharmacological therapies have been developped tocontrol the risk factors associated to CVD. Fibrates areable to correct dyslipidemia, therefore decreasing CVDrisk. Thiazolidinediones (TZD) or glitazones by increa-sing insulin sensitivity decrease plasma glucose levels indiabetic patients. Both fibrates and TZD activate theperoxisome proliferator-activated receptors (PPARs), afamily of nuclear receptors that play a central role in thecontrol of lipid and glucose metabolism. In this review,we will discuss the mode of action of fibrates and TZDand we will present an overview on PPAR ligands underdevelopment. ◊REFERENCES 1. Beckman JA, Creager MA,Libby P. Diabetes andatherosclerosis:epidemiology,pathophysiology, andmanagement